KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Treasury Shares (2018 - 2025)

Amneal Pharmaceuticals (AMRX) has 8 years of Treasury Shares data on record, last reported at $2.2 million in Q4 2025.

  • For Q4 2025, Treasury Shares fell 20.84% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $2.2 million, down 20.84%, while the annual FY2025 figure was $2.2 million, 20.84% down from the prior year.
  • Treasury Shares reached $2.2 million in Q4 2025 per AMRX's latest filing, down from $2.8 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $17.9 million in Q4 2022 and bottomed at $2.2 million in Q4 2025.
  • Average Treasury Shares over 5 years is $10.7 million, with a median of $13.2 million recorded in 2021.
  • Peak YoY movement for Treasury Shares: surged 44.36% in 2021, then tumbled 83.93% in 2024.
  • A 5-year view of Treasury Shares shows it stood at $13.2 million in 2021, then surged by 35.99% to $17.9 million in 2022, then dropped by 2.64% to $17.5 million in 2023, then crashed by 83.93% to $2.8 million in 2024, then dropped by 20.84% to $2.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $2.2 million in Q4 2025, $2.8 million in Q4 2024, and $17.5 million in Q4 2023.